|
1
|
Hou R, Cao B and Chen Z, Li Y, Ning T, Li
C, Xu C and Chen Z: Association of cytotoxic T
lymphocyte-associated antigen-4 gene haplotype with the
susceptibility to gastric cancer. Mol Biol Rep. 37:515–520. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen WQ, Zheng RS, Zhang SW, Zeng HM and
Zou XN: The incidences and mortalities of major cancers in China,
2010. Chin J Cancer. 33:402–405. 2014.PubMed/NCBI
|
|
3
|
Lissoni P, Brivio F, Ardizzoia A, Tancini
G and Barni S: Subcutaneous therapy with low-dose interleukin-2
plus the neurohormone melatonin in metastatic gastric cancer
patients with low performance status. Tumori. 79:401–404.
1993.PubMed/NCBI
|
|
4
|
Bhutia SK, Das SK, Azab B, Menezes ME,
Dent P, Wang XY, Sarkar D and Fisher PB: Targeting breast
cancer-initiating/stem cells with melanoma
differentiation-associated gene-7/interleukin-24. Int J Cancer.
133:2726–2736. 2013.PubMed/NCBI
|
|
5
|
Menezes ME, Shen XN, Das SK, Emdad L, Guo
C, Yuan F, Li YJ, Archer MC, Zacksenhaus E, Windle JJ, et al:
MDA-7/IL-24 functions as a tumor suppressor gene in vivo in
transgenic mouse models of breast cancer. Oncotarget.
6:36928–36942. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sauane M, Gupta P, Lebedeva IV, Su ZZ,
Sarkar D, Randolph A, Valerie K, Gopalkrishnan RV and Fisher PB:
N-glycosylation of MDA-7/IL-24 is dispensable for tumor
cell-specific apoptosis and ‘bystander’ antitumor activity. Cancer
Res. 66:11869–11877. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tong AW, Nemunaitis J, Su D, Zhang Y,
Cunningham C, Senzer N, Netto G, Rich D, Mhashilkar A, Parker K, et
al: Intratumoral injection of INGN 241, a nonreplicating
adenovector expressing the melanoma-differentiation associated
gene-7 (mda-7/IL24): Biologic outcome in advanced cancer patients.
Mol Ther. 11:160–172. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen X, Liu D, Wang J, Su Q, Zhou P, Liu
J, Luan M and Xu X: Suppression effect of recombinant adenovirus
vector containing hIL-24 on Hep-2 laryngeal carcinoma cells. Oncol
Lett. 7:771–777. 2014.PubMed/NCBI
|
|
9
|
Hurst DR and Welch DR: Metastasis
suppressor genes at the interface between the environment and tumor
cell growth. Int Rev Cell Mol Biol. 286:107–180. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yao JC, Mansfield PF, Pisters PW, Feig BW,
Janjan NA, Crane C and Ajani JA: Combined modality the therapy for
gastric cancer. Semin Surg Oncol. 21:223–227. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qu Y, Zhou C, Zhang J, Cai Q, Li J, Du T,
Zhu Z, Cui X and Liu B: The metastasis suppressor SOX11 is an
independent prognostic factor for improved survival in gastric
cancer. Int J Oncol. 44:1512–1520. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Panneerselvam J, Munshi A and Ramesh R:
Molecular targets and signaling pathways regulated by interleukin
(IL)-24 in mediating its antitumor activities. J Mol Signal.
8:152013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang H, Lin JJ, Su ZZ, Goldstein NI and
Fisher PB: Subtraction hybridization identifies a novel melanoma
differentiation associated gene, mda-7, modulated during human
melanoma differentiation, growth and progression. Oncogene.
11:2477–2486. 1995.PubMed/NCBI
|
|
15
|
Chada S, Sutton RB, Ekmekcioglu S,
Ellerhorst J, Mumm JB, Leitner WW, Yang HY, Sahin AA, Hunt KK,
Fuson KL, et al: Mda-7/IL-24 is a unique cytokine-tumor suppressor
in the IL-10 family. Int Immunopharmacol. 4:649–667. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lebedeva IV, Emdad L, Su ZZ, Gupta P,
Sauane M, Sarkar D, Staudt MR, Liu SJ, Taher MM, Xiao R, et al:
mda-7/IL-24, novel anticancer cytokine: Focus on bystander
antitumor, radiosensitization and antiangiogenic properties and
overview of the phase I clinical experience (Review). Int J Oncol.
31:985–1007. 2007.PubMed/NCBI
|
|
17
|
Menezes ME, Bhatia S, Bhoopathi P, Das SK,
Emdad L, Dasgupta S, Dent P, Wang XY, Sarkar D and Fisher PB:
MDA-7/IL-24: Multifunctional cancer killing cytokine. Adv Exp Med
Biol. 818:127–153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie Y, Sheng W, Xiang J, Ye Z, Zhu Y, Chen
X and Yang J: Recombinant human IL-24 suppresses lung carcinoma
cell growth via induction of cell apoptosis and inhibition of tumor
angiogenesis. Cancer Biother Radiopharm. 23:310–320. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma G, Kawamura K, Shan Y, Okamoto S, Li Q,
Namba M, Shingyoji M, Tada Y, Tatsumi K, Hiroshima K, et al:
Combination of adenoviruses expressing melanoma
differentiation-associated gene-7 and chemotherapeutic agents
produces enhanced cytotoxicity on esophageal carcinoma. Cancer Gene
Ther. 21:31–37. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pan X, Sheng W, Zhu Q, Xie Y, Ye Z, Xiang
J, Li D and Yang J: Inhibition of pancreatic carcinoma growth by
adenovirus-mediated human interleukin-24 expression in animal
model. Cancer Biother Radiopharm. 23:425–434. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen X, Liu D, Wang J, Su Q, Zhou P, Liu
J, Luan M and Xu X: Suppression effect of recombinant adenovirus
vector containing hIL-24 on Hep-2 laryngeal carcinoma cells. Oncol
Lett. 7:771–777. 2014.PubMed/NCBI
|
|
22
|
Patani N, Douglas-Jones A, Mansel R, Jiang
W and Mokbel K: Tumour suppressor function of MDA-7/IL-24 in human
breast cancer. Cancer Cell Int. 10:292010.PubMed/NCBI
|
|
23
|
Shamir ER and Ewald AJ: Adhesion in
mammary development: Novel roles for E-cadherin in individual and
collective cell migration. Curr Top Dev Biol. 112:353–382. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sarrió D, Palacios J, Hergueta-Redondo M,
Gómez-López G, Cano A and Moreno-Bueno G: Functional
characterization of E-and P-cadherin in invasive breast cancer
cells. BMC Cancer. 9:742009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sounni NE and Noel A: Membrane type-matrix
metalloproteinases and tumor progression. Biochimie. 87:329–342.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tao L, Li Z, Lin L, Lei Y, Hongyuan Y,
Hongwei J, Yang L and Chuize K: MMP1, 2, 3, 7, and 9 gene
polymorphisms and urinary cancer risk: A meta-analysis. Genet Test
Mol Biomarkers. 19:548–555. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Belotti D, Paganoni P, Manenti L, Garofalo
A, Marchini S, Taraboletti G and Giavazzi R: Matrix
metalloproteinases (MMP9 and MMP2) induce the release of vascular
endothelial growth factor (VEGF) by ovarian carcinoma cells:
Implications for ascites formation. Cancer Res. 63:5224–5229.
2003.PubMed/NCBI
|
|
28
|
Bánky B, Rásó-Barnett L, Barbai T, Tímár
J, Becságh P and Rásó E: Characteristics of CD44 alternative splice
pattern in the course of human colorectal adenocarcinoma
progression. Mol Cancer. 11:832012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Paulis YW, Huijbers EJ, van der Schaft DW,
Soetekouw PM, Pauwels P, Tjan-Heijnen VC and Griffioen AW: CD44
enhances tumor aggressiveness by promoting tumor cell plasticity.
Oncotarget. 6:19634–19646. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dent P, Yacoub A, Grant S, Curiel DT and
Fisher PB: MDA-7/IL-24 regulates proliferation, invasion and tumor
cell radiosensitivity: A new cancer therapy? J Cell Biochem.
95:712–719. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cunningham CC, Chada S, Merritt JA, Tong
A, Senzer N, Zhang Y, Mhashilkar A, Parker K, Vukelja S, Richards
D, et al: Clinical and local biological effects of an intratumoral
injection of mda-7 (IL24; INGN 241) in patients with advanced
carcinoma: A phase I study. Mol Ther. 11:149–159. 2005. View Article : Google Scholar : PubMed/NCBI
|
